Objective  To evaluate the prevalence, clinical characteristics, and risk factors of untreated patients with newly diagnosed chronic obstructive pulmonary disease (COPD) with hypertension.

  Methods  A total of 569 newly diagnosed COPD patients were selected by cross-sectional population screening, and divided into COPD patients with hypertension group (n=249) and COPD patients without hypertension group (n=320). Respiratory symptoms, quality of life score and blood indexes were observed in the two groups; high risk factors of newly diagnosed COPD with hypertension were analyzed.

  Results  The mean age, male ratio, body mass index (BMI) and smoking index in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The rates of diabetes and cardiovascular disease in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The score of modified medical research council (mMRC) and COPD assessment test (CAT) in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The total white blood cell count, neutrophils count, eosinophils count and monocytes count in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The levels of venous fasting blood glucose, triglyceride, uric acid and serum creatinine in the COPD with hypertension group were significantly higher, and the levels of high-density lipoprotein cholesterol were significantly lower than those in the COPD without hypertension group (P < 0.05). Older age, obesity, elevated fasting blood glucose and absolute monocyte value are independent risk factors for COPD with hypertension.

  Conclusion  COPD patients with increasing age, obesity, increased monocyte count, and hyperglycemia are more likely to be accompanied by hypertension, and their quality of life is poor. It is of great significance to comprehensively evaluate and monitor the metabolic status of COPD patients, control risk factors and reduce the incidence of complications.